Updated:
Envoy Medical, Inc.
Envoy Medical, Inc. is a medical device firm developing implantable hearing solutions for hearing loss.
Envoy Medical, Inc.
Envoy Medical, Inc. is a publicly traded medical device company headquartered in White Bear Lake, Minnesota. The company was originally founded in 2004 and has since focused on developing fully implantable hearing devices. Its product portfolio includes the Esteem® implantable hearing system, which received FDA approval in 2010 for moderate to severe sensorineural hearing loss, and the Acclaim® cochlear implant system, currently in clinical trials. The firm operates through a direct sales model and partners with hospital systems and audiology clinics across the United States. Envoy Medical raises capital through follow-on equity offerings and venture debt. As of its 2024 annual filing, the firm reported total assets of approximately $26.5 million and no AUM in the traditional asset-management sense. The company serves the ear, nose, and throat (ENT) and audiology market, competing with larger incumbents like Cochlear Ltd. and MED-EL. Its strategy hinges on securing regulatory approvals and expanding insurance reimbursement coverage. The firm's team includes a board of directors and executive officers drawn from medical device and pharmaceutical backgrounds. In November 2024, Envoy Medical appointed a new Chief Financial Officer per SEC filings. The company maintains a single office in White Bear Lake, MN. It does not operate philanthropic or asset-management vehicles—its sole structure is a publicly held corporation with no related family-office entity. Envoy Medical's structural differentiator is its fully implantable hearing technology, which avoids the external hardware required by conventional cochlear and hearing aids. This architecture eliminates daily cleaning and battery changes for patients, though it requires surgical implantation and regular replacement of the internal battery. The company must demonstrate long-term durability and cost-effectiveness relative to existing partially implantable systems.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Envoy Medical?
Envoy Medical is a publicly traded company; investment decisions are made by its board of directors and executive leadership, including the CEO and CFO. The board oversees capital allocation, R&D spending, and strategic partnerships. No single family office or individual principal controls the firm's investment strategy. Per SEC filings, the current CEO is Brent MacLaurin.
How does Envoy Medical source proprietary technology?
Envoy Medical develops its technology internally through R&D and holds patents on its fully implantable hearing systems. It does not maintain a venture or acquisition pipeline. The firm has historically licensed or acquired intellectual property, such as the core Esteem technology from other developers. It also collaborates with academic and clinical partners for trial design and data generation.
Is Envoy Medical structured as a family office?
No. Envoy Medical, Inc. is a publicly traded medical device company (NASDAQ: COCH). It has no family-office structure, no wealth-management arm, and no affiliated family holding company. The firm's sole business is developing and selling hearing implant systems to healthcare providers and patients.
Does Envoy Medical participate in fund commitments or direct deals?
Envoy Medical does not participate in fund commitments. As an operating company, it raises capital through public equity offerings and debt. It has not disclosed any direct investments in other firms or co-investment partnerships. The firm's capital-raising events include follow-on stock offerings and the use of at-the-market equity programs.
What investment stages does Envoy Medical typically target?
Envoy Medical does not target investment stages—it is not an investment firm. The company itself is in the regulatory and commercialization stage for its hearing products. Its capital deployment is focused on clinical trials, FDA submissions, manufacturing scale-up, and sales force expansion. The firm targets milestones such as regulatory approval but does not externally allocate capital.
Which sectors does Envoy Medical explicitly avoid?
As a medical device company, Envoy Medical does not invest in sectors. Its product focus is exclusively on otology—specifically implantable hearing devices. The firm does not engage in pharmaceuticals, diagnostics, or non-medical technologies. Its R&D pipeline is limited to hearing restoration and enhancement.
How is Envoy Medical related to any parent or spinout firm?
Envoy Medical is an independent public company; it is not a subsidiary or spinout of any other firm. It was formed from a merger between a predecessor entity and a blank-check company in 2020. The firm has no disclosed relationship with any family office, venture firm, or asset manager.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: